Extensive Cutaneous and Scalp Metastases From Hormone Receptor-Positive Breast Cancer Successfully Treated With CDK4/6 Inhibitor Therapy: A Case Report.

At eight years of follow-up, the MONARCH 3 trial showed that patients receiving abemaciclib plus an aromatase inhibitor achieved a median OS of 66.8 months compared with 53.7 months in the control arm in the intention-to-treat population, corresponding to an absolute difference of 13.1 months; however, this difference did not reach statistical significance (HR 0.804; 95% CI 0.637-1.015; p = 0.0664) [ 44 ].

also in 111,027 other papers